COPD Exacerbation Acute Clinical Trial
Official title:
The Effect of Airway Oscillation and Chest Wall Oscillation on Respiratory Functions and Sleep Quality in COPD Patients in Acute Exacerbation Period and Technical Inspection of Devices
Chronic obstructive pulmonary disease (COPD); It is a common, treatable and preventable disease characterized by progressive and irreversible airflow limitation and has systemic effects with respiratory system involvement. Increased respiratory workload, decreased work .
Status | Recruiting |
Enrollment | 27 |
Est. completion date | June 17, 2024 |
Est. primary completion date | June 10, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 40 Years and older |
Eligibility | Inclusion Criteria: - Being classified as GOLD stage 3 or 4 based on spirometric evaluation in the medical history. - Having a hospital admission within the specified time frame, evaluated by a pulmonary specialist, and admitted to the pulmonary diseases service with a diagnosis of COPD exacerbation. - Being 40 years of age or older. - Voluntarily agreeing to participate in the study. Exclusion Criteria: - Having a hospital admission with a diagnosis of asthma attack in the last 5 years. - Monitoring suspicious focal points for pneumonia on lung radiology. - Hospitalization due to reasons other than exacerbation despite having a diagnosis of COPD. - Presence of pulmonary fibrosis or suspicious findings of fibrosis on radiology. - Systemic fungal infections. - Having cognitive impairment affecting the decision to participate in the study, such as confusion, orientation disorder, or dementia. - Patients with lung cancer or metastasis in the lungs. - Diagnosis of conditions provoking shortness of breath other than COPD exacerbation, such as pneumonia, pneumothorax, heart failure, and pulmonary embolism. - Presence of a new-onset rhythm disorder or ischemic changes requiring intervention on the EKG, excluding sinus tachycardia and multifocal atrial tachycardia. - Chronic kidney failure requiring hemodialysis. - Patients with conditions causing weakness in the lower extremities, such as arthritis, neurological disease, deep vein thrombosis, peripheral artery disease, muscle weakness, fractures, osteoarthritis, etc. - Having ankylosing spondylitis with a Cobb angle of 10 degrees or more in the radiographic evaluation of the vertebral column. - Having undergone surgery on the upper extremities, lower extremities, neck, and back. |
Country | Name | City | State |
---|---|---|---|
Turkey | University of Health Sciences | Istanbul |
Lead Sponsor | Collaborator |
---|---|
Saglik Bilimleri Universitesi | Gulhane Training and Research Hospital |
Turkey,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | COPD assessment test | The COPD assessment test (CAT) includes eight items related to the severity of dyspnea, exercise capacity, cough, sputum, chest tightness, sleep quality, self-confidence, and energy levels. The CAT is a short and simple instrument to evaluate COPD patients, and its validated translations are present in a broad range of languages in the world. Additionally, the CAT is correlated with quality of life. According to the GOLD guidelines, patients with CAT score of =10 or mMRC score of =2 represents have more prominent symptoms. The cutoff points of more symptoms for CAT score =10 was validated in COPD. This threshold has been detected to have an important impact on the daily lives of patients with COPD. | The first and last day of the training will be measured an avarage 7 days | |
Primary | Clinical COPD Questionnaire | The Clinical COPD Questionnaire, developed by Thys Van der Molen, consisting of 10 items (4 items for symptoms, 4 items for functional status, and 2 items for mental status) assessing clinical control for the purpose of evaluating functional status, mental status, and symptoms, will be administered to all cases. In a study conducted by Reda and colleagues in 2010, it was demonstrated that the Clinical COPD Questionnaire is a valid, reliable, and sensitive tool for use in individuals at risk of COPD and in COPD patients | The first and last day of the training will be measured an avarage 7 days | |
Primary | mMRC dyspnea scale | The perception of dyspnea in patients will be assessed using the mMRC dyspnea scale. This scale, modified by ATS, evaluates dyspnea and limitations in daily life activities. Patients are asked to choose the most suitable expression from the five statements ranging from '0-4' (0: Only shortness of breath during heavy exercise; 4: Being housebound due to breathlessness, experiencing shortness of breath even during light activities such as dressing and undressing) to describe their own perception of dyspnea. The scale developed by Richards in 1987 consists of 6 items assessing the depth of nocturnal sleep, sleep onset latency, frequency of awakening, duration of wakefulness upon awakening, sleep quality, and ambient noise level. Each item is evaluated on a visual analog scale ranging from 0 to 100. Scores between "0-25" indicate very poor sleep, while scores between "76-100" indicate very good sleep. The scale's total score is assessed based on 5 items, excluding the 6th item evaluating | The first and last day of the training will be measured an avarage 7 days | |
Primary | Richard-Campbell Sleep Questionnaire | The scale developed by Richards in 1987 consists of 6 items assessing the depth of nocturnal sleep, sleep onset latency, frequency of awakening, duration of wakefulness upon awakening, sleep quality, and ambient noise level. Each item is evaluated on a visual analog scale ranging from 0 to 100. Scores between "0-25" indicate very poor sleep, while scores between "76-100" indicate very good sleep. The scale's total score is assessed based on 5 items, excluding the 6th item evaluating ambient noise level from the overall score. As the score on the scale increases, patients' sleep quality also improves. The Cronbach's alpha value for the scale, developed by Richards, was found to be 0.82. The Turkish validity and reliability of the scale were conducted by Özlü and Özer, revealing a Cronbach's alpha value of 0.91 | The first and last day of the training will be measured an avarage 7 days | |
Primary | 30 second sit and stand | test is primarily used for evaluating function and physical performance associated with mobility, and is suggested as an acceptable alternative method for assessing functional capacity in COPD. The patient, who has received medical treatment in an environment equipped with a chair with a seat height of approximately 44 cm and a backrest, preferably without armrests, a stopwatch, oxygen support if needed, a blood pressure monitor, and a defibrillator, and has not engaged in heavy activity in the last 2 hours, will be explained the test procedure in a comprehensible manner. Resting blood pressure, oxygen saturation, pulse, and modified Borg dyspnea score will be recorded. The patient will be instructed to cross their arms and touch both shoulders, then sit and stand up from the chair for 30 seconds in this position. At the end of the test, blood pressure, oxygen saturation, pulse, modified Borg dyspnea score, and the number of sit-to-stand repetitions within 30 seconds will be record | The first and last day of the training will be measured an avarage 7 days | |
Primary | BODE index | The BODE index has been developed to assess the mortality risk in patients with COPD. The BODE index comprises parameters such as BMI (Body Mass Index), the severity of airflow limitation, perceived degree of dyspnea, and exercise capacity. BMI will be calculated using the weight/height² formula, the severity of airflow limitation will be assessed by FEV1 % predicted, the perceived degree of dyspnea will be evaluated using the mMRC scale, and exercise capacity will be determined with the 6MWT (6-Minute Walk Test) in patients with COPD. | The first and last day of the training will be measured an avarage 7 days | |
Primary | chest circumference measurements | To assess chest mobility and respiratory type, chest circumference measurements will be taken using a tape measure at axillary (at the level of the 4th rib), epigastric (at the xiphoid process level), and subcostal (above the 11th and 12th ribs) regions. Measurements will be taken in an upright sitting position, during neutral, deep inspiration, and deep expiration. The difference between deep inspiration and deep expiration will be recorded in centimeters | The first and last day of the training will be measured an avarage 7 days | |
Primary | Modified Borg Scale | This scale was developed by Borg in 1970 for the purpose of measuring the perceived exertion during physical exercise. It is commonly used to assess the intensity of dyspnea during effort and at rest. Comprising ten grades that describe the severity of dyspnea, the Modified Borg Scale (MBS) makes it easier for patients by providing clear definitions for the intensity of dyspnea | The first and last day of the training will be measured an avarage 7 days | |
Primary | muscle strenght test | Muscle strength testing is used to determine the capability of the muscle or muscle group to produce force. It provides information that is useful in differential diagnosis, prognosis and management of neuromuscular and musculoskeletal disorders. its evaluating muscle strength is the Oxford Scale (AKA Medical Research Council Manual Muscle Testing scale). This method involves testing key muscles from the upper and lower extremities against the examiner's resistance and grading the patient's strength on a 0 to 5 scale accordingly | The first and last day of the training will be measured an avarage 7 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT05418777 -
Treatment of Pneumocystis in COPD (the TOPIC Study)
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT05649891 -
Checklists Resuscitation Emergency Department
|
N/A | |
Completed |
NCT03286855 -
Effectiveness of Vibrating Mesh Versus Small Volume Nebuliser in Chronic Obstructive Pulmonary Disease (COPD)
|
N/A | |
Recruiting |
NCT06021990 -
Clopidogrel for the Prevention of Exacerbations in Severe COPD
|
Phase 3 | |
Completed |
NCT05218525 -
Testing a Prediction Algorithm Into a Running Telehealth System for Patients With COPD
|
N/A | |
Recruiting |
NCT06149494 -
RCT of Vapendavir in Patients With COPD and Human Rhinovirus/Enterovirus Upper Respiratory Infection
|
Phase 2 | |
Recruiting |
NCT05734365 -
COPD-ICU Multicentre Prospective Observational Register
|
||
Completed |
NCT03464695 -
Automated Oxygen Delivery by O2matic to Patients Admitted With an Exacerbation in COPD
|
N/A | |
Recruiting |
NCT04881409 -
Nasal High-flow Compared to Non-invasive Ventilation in Treatment of Acute Acidotic Hypercapnic Exacerbation of Chronic Obstructive Pulmonary Disease
|
N/A | |
Completed |
NCT05182294 -
Tolerance and Acute Effects of a New HFNT Nasal Cannula
|
N/A | |
Completed |
NCT04821869 -
ProAir Digihaler in COPD Disease Management: A Real World Study
|
||
Recruiting |
NCT05783544 -
Impact of A. Lumbricoides on Pulmonary Aspergillosis Development
|
N/A | |
Recruiting |
NCT06331416 -
Multiparametric Home Telemonitoring of Patients With Chronic Obstructive Pulmonary Disease Exacerbation
|
N/A | |
Not yet recruiting |
NCT05703919 -
Standard vs Targeted Oxygen Therapy Prehospital for Chronic Obstructive Pulmonary Disease
|
Phase 4 | |
Not yet recruiting |
NCT06419062 -
The Use of Medical Devices to Monitor Chronic Obstructive Pulmonary Disease Patients Study BREATH-TRACHER 2
|
||
Not yet recruiting |
NCT06419036 -
The Use of Medical Devices to Monitor Chronic Obstructive Pulmonary Disease Patients Study BREATH-TRACHER 1
|
||
Recruiting |
NCT05764993 -
Prevalence of Humoral Dysfunction in Pts With Frequent Exacerbations of COPD, and the Effect of SCIgR for Prevention
|
Phase 2 | |
Completed |
NCT06040931 -
Airway Inflammation, Small Airways Dysfunction, and Frequency of Exacerbations in COPD
|
N/A | |
Active, not recruiting |
NCT04192175 -
Identification of Patients Admitted With COPD Exacerbations and Predicting Readmission Risk Using Machine Learning
|
||
Recruiting |
NCT03680495 -
Steroid Resistance During COPD Exacerbations With Respiratory Failure
|